Skip to content

Clinical, Histological and Prognostic Forms of Adenocarcinoma of the Anus

Clinical, Histological and Prognostic Forms of Adenocarcinoma of the Anus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05605873
Acronym
ProCHADA
Enrollment
46
Registered
2022-11-04
Start date
2022-09-16
Completion date
2023-12-31
Last updated
2022-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Adenocarcinoma

Brief summary

Adenocarcinoma of the anus is rare. It concerns less than 10% of anal cancers and its incidence is less than 0.2/100 000 inhabitants. Its management is not consensual and is most often derived by analogy with that of adenocarcinoma of the lower rectum. This is due to the rarity but also to the diversity of anatomical (anal margin, anal canal, lower rectum), etiological (primary glandular tumors or secondary to anal fistula, primary distant tumor and/or Crohn's disease) and histological forms (mucinous, intestinal, glandular adenocarcinomas and primary or secondary Paget's disease). Most of the literature consists of small case series and simple clinical cases in which the prognosis of these subforms has not been studied.

Interventions

None listed

Sponsors

Fondation Hôpital Saint-Joseph
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient over 18 years of age * French-speaking patient * Patient with a diagnosis of adenocarcinoma of the anus between 01/01/2006 and 30/06/2022 in participating centers

Exclusion criteria

* Patient under guardianship or curatorship * Patient deprived of liberty * Patient under court protection * Patient objecting to the use of his data for this research

Design outcomes

Primary

MeasureTime frameDescription
Risk of mortality at 1 year, estimated using a survival curveYear1This outcome corresponds to the 1 year mortality rates after diagnosis of adenocarcinoma of the anus.
Risk of mortality at 5 years, estimated using a survival curveYear5This outcome corresponds to the 5 year mortality rates after diagnosis of adenocarcinoma of the anus.

Secondary

MeasureTime frameDescription
Adaptaion of the therapeutic management according to the clinical and histological formYear5This outcome corresponds to the Proposed treatments (local excision, abdominoperineal amputation, neoadjuvant treatment, adjuvant treatment, etc.) according to the clinical and histological form.
Search for prognostic factors of severity in all formsYear5This outcome corresponds to the Prognostic factors of severity for all forms.
Compare prognosis by clinical and histological formYear5This outcome corresponds to the Mortality rate by clinical and histological form.
Describe their therapeutic managementYear5This outcome corresponds to the Proposed treatments (local excision, abdominal-perineal amputation, neoadjuvant treatment, adjuvant treatment, etc.).
Describe the various anatomical, etiological and histological formsYear5This outcome corresponds to the classification of anatomical (anal margin, anal canal, lower rectum), etiological (primary glandular tumors or secondary to anal fistula, primary distant tumor and/or Crohn's disease) and histological (mucinous, intestinal, glandular adenocarcinoma and primary or secondary Paget's disease) forms.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026